Avicanna Reveals Pre-Clinical Findings Indicating Improved Absorption and Submits Patent Application for Innovative Oral Delivery System

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Nov 19 2025

0mins

Source: Newsfilter

Novel Drug Delivery Platform: Avicanna Inc. has developed a new drug delivery platform, PwdRx, which shows superior bioavailability and faster absorption of cannabinoids in preclinical studies, addressing challenges related to the solubility and effectiveness of cannabinoids like CBD and THC.
Provisional Patent Application: The company has filed a provisional patent application for the PwdRx platform, which can be utilized in various pharmaceutical formats such as tablets and capsules, and is designed to enhance drug stability and release capabilities.
Clinical Implications: The PwdRx technology aims to improve treatment options for patients with conditions related to pain and inflammation, potentially allowing healthcare providers to tailor therapies more effectively.
Company Overview: Avicanna is a biopharmaceutical company focused on cannabinoid-based products, with a diverse portfolio that includes a range of proprietary formulations and a commitment to advancing cannabinoid science and technology.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.